Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWC36Y)

• Drug Name: OMS405 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Nicotine dependence	6C4A.2	Phase 2	[1]
Opioid dependence	6C43.2Z	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 67599
  TTD Drug ID: DMWC36Y

Molecule-Related Drug Atlas

Drug(s) Targeting Peroxisome proliferator-activated receptor gamma (PPAR-gamma)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[4]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[5]
Lobeglitazone	DMHY3IP	Type-2 diabetes	5A11	Approved	[6]
Rosiglitazone XR	DMT45MU	Type-2 diabetes	5A11	Approved	[7]
Thiazolidinedione	DMC1NBW	Alzheimer disease	8A20	Approved	[5]
Glitazone	DMDN4A1	N. A.	N. A.	Phase 4	[8]
MURAGLITAZAR	DMG3NFZ	N. A.	N. A.	Phase 3	[9]
Rivoglitazone	DMBY31K	Ocular inflammation	9C61.24	Phase 3	[10]
Balaglitazone	DMXBHR6	Type-1 diabetes	5A10	Phase 3	[11]
Ragaglitazar	DMFSHEM	Type-1 diabetes	5A10	Phase 3	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)	TTZMAO3	PPARG_HUMAN	Agonist	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035962)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of Avarx.
• [4] Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
• [5] Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
• [6] Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
• [7] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [8] Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
• [9] Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
• [10] A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13.
• [11] Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97.
• [12] Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.